Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

InnoCare Pharma has announced that its Phase II clinical study of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for ...

Alex Thompson CFA, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Oruka Therapeutics (ORKA). Alex Thompson CFA has given ...

Mild. Only a few spots cover about 3% of ... which will require long-term treatment. Guttate psoriasis can emerge temporarily and often goes away on its own. But it’s good to get an accurate ...

Dermatologists recently have developed and validated several tools for assessing itch in plaque psoriasis, such as the Peak ...

InnoCare Pharma’s tyrosine kinase 2 (TYK2) inhibitor has hit the main goals of a phase 2 trial in China, sustaining the ...

A dermatologist — a doctor who specializes in treating skin, hair, and nail conditions — will most likely recommend topical treatments for nail psoriasis if you have mild symptoms that only ...

These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that phase II clinical study results of ...